Trial Profile
Combined use of bortezomib, cyclophosphamide, and dexamethasone induces favorable hematological and organ responses in Japanese patients with amyloid light-chain amyloidosis: a single-institution retrospective study.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Dec 2015
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Cyclophosphamide; Dexamethasone
- Indications Amyloid light-chain amyloidosis
- Focus Therapeutic Use
- 06 Dec 2015 New trial record